<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">Wang et al. reported that remdesivir firmly inhibits interference with SARS-CoV-2 at low micromolar (μM) concentrations but has a high selectivity index (Half Maximum Effective Concentration (EC50), 0.77 μM; Half Cytotoxic Concentration (CC50) &gt; 100 μM; IS &gt; 129.87) (
 <xref rid="bib147" ref-type="bibr">Wang et al., 2020b</xref>). Holshue et al. documented that remdesivir brought results that were remarkable in the care of a first COVID-19 patient in the United States (
 <xref rid="bib57" ref-type="bibr">Holshue et al., 2020</xref>). Various clinical trials have been initiated to determine the drug's safety and efficacy in COVID-19 infected patients.
</p>
